A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent®

PHASE1CompletedINTERVENTIONAL

Enrollment

198

Participants

Timeline

Start Date

August 31, 2024

Primary Completion Date

November 15, 2024

Study Completion Date

December 27, 2024

Conditions

Atopic Dermatitis

Interventions

DRUG

QL2108 injection

300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection

DRUG

Dupixent®

300mg/2.0mL; single dose; prefilled syringe; subcutaneous injection

Trial Locations (1)

Jinan Central Hospital, Jinan

All Listed Sponsors

lead

Qilu Pharmaceutical Co., Ltd.

INDUSTRY

NCT06614907 - A PhaseⅠ Comparative Study to Evaluate the Pharmacokinetics of QL2108 to Dupixent® | Biotech Hunter | Biotech Hunter